Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
Open Access
- 2 April 2010
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 122 (1), 181-188
- https://doi.org/10.1007/s10549-010-0866-3
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysisThe Lancet Oncology, 2009
- Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic AgentsCancer Investigation, 2009
- Osteonecrosis of the jawSkeletal Radiology, 2008
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous CancerJournal of Clinical Oncology, 2007
- Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancerAnnals of Oncology, 2006
- Systematic Review: Bisphosphonates and Osteonecrosis of the JawsAnnals of Internal Medicine, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Osteonecrosis of the Jaw and BisphosphonatesThe New England Journal of Medicine, 2005